We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
PEN Stock Up Following Q4 Earnings & Revenue Beat, Margins Rise
Read MoreHide Full Article
Key Takeaways
PEN reported Q4 adjusted EPS of $1.18, topping estimates as revenues rose 22.1% year over year.
Penumbra's U.S. sales climbed 20.6%, driving growth in Thrombectomy and Embolization products.
PEN expanded gross margin to 68% and lifted operating margin to 13.4% in Q4.
Penumbra, Inc. (PEN - Free Report) reported fourth-quarter 2025 adjusted earnings per share (EPS) of $1.18 compared with 85 cents in the year-ago quarter. The figure surpassed the Zacks Consensus Estimate by 5.36%.
GAAP earnings were $1.20 per share compared with 86 cents in the prior-year period.
For the full year, adjusted EPS came in at $3.84, up 82.9% year over year.
PEN’s Revenues
Penumbra registered revenues of $385.4 million in the reported quarter, up 22.1% year over year on a reported basis and 20.9% at constant exchange rate or CER. The figure topped the Zacks Consensus Estimate by 6.74%.
For the full year, revenues were $1.40 billion, reflecting a 17.5% rise from the year-ago period (16.9% at CER).
Since the Feb. 25 announcement, PEN shares have risen 1.7%, closing at $344.39 on Friday.
Penumbra’s Q4 Results in Detail
The company reports under two geographical segments — theUnited States and International.
PEN recorded revenues of $299.1 million (77.6% total revenues) in the United States, up 20.6% year over year on a reported basis.
Revenues in the International segment increased 27.7% on a reported basis (up 20.9% in CER) to $86.3 million (22.4% of total revenues).
The company currently reports its product revenues under two categories — Thrombectomy, and Embolization and Access.
The company registered revenues of $254.7 million from sales of Thrombectomy products, up 15.7% on a reported basis and 14.7% at CER.
Sales of Embolization and Access products totaled $130.7 million, up 22.1% on a reported basis and 20.9% at CER.
PEN’s Q4 Margin Performance
In the reported quarter, Penumbra’s gross profit improved 24.4% year over year to $262.1 million. The gross margin expanded 123 basis points (bps) to 68% despite a 17.6% rise in the cost of revenues.
Selling, general and administrative expenses rose 22.4% to $181.1 million. Research and development expenses totaled $21.8 million, up 8.9% year over year. Adjusted operating profit came in at $59.2 million compared with $42.8 million in the comparable 2024 period. The adjusted operating margin expanded 181 bps year over year to 13.4%.
PEN’s Financial Update
Penumbra exited the fourth quarter of 2025 with cash and marketable investments of $544.8 million compared with $340.1 million at the end of 2024.
Penumbra Halts 2026 Guidance
In January 2026, Penumbra announced a definitive agreement to be acquired by Boston Scientific in a cash and stock transaction, valuing the company at $374 per share or approximately $14.5 billion in enterprise value. The transaction is expected to be completed in 2026, subject to PEN stockholders’ approval and the satisfaction of other customary closing conditions. In light of this proposed acquisition, Penumbra stopped providing financial guidance for full-year 2026.
Our Take on PEN Stock
Penumbra exited the fourth quarter of 2025 with better-than-expected earnings and revenues. Sales growth of global thrombectomy products, and global embolization and access products were both driven by the U.S. performance. The expansion of both margins is also highly encouraging.
During the quarter, the company announced results from the landmark STORM-PE randomized controlled trial, which found that the use of mechanical thrombectomy, specifically computer-assisted vacuum thrombectomy, with anticoagulation achieved a superior reduction in right heart strain compared to anticoagulation therapy alone in patients with acute intermediate-high risk pulmonary embolism. Findings also showed significantly greater improvements in thrombus burden reduction, heart rate, oxygen requirement and functional outcomes.
PEN’s Zacks Rank and Key Picks
Currently, Penumbra carries a Zacks Rank #4 (Sell).
Some better-ranked stocks from the broader medical space are Intuitive Surgical (ISRG - Free Report) , Cardinal Health (CAH - Free Report) and Align Technology (ALGN - Free Report) .
Intuitive Surgical, currently sporting a Zacks Rank #1 (Strong Buy), reported a fourth-quarter 2025 adjusted EPS of $2.53, which surpassed the Zacks Consensus Estimate by 12.4%. Revenues of $2.87 billion beat the Zacks Consensus Estimate by 4.7%. You can see the complete list of today’s Zacks #1 Rank stocks here.
ISRG has an estimated long-term earnings growth rate of 15.7% compared with the industry’s 12.7% growth. The company beat earnings estimates in each of the trailing four quarters, the average surprise being 13.24%.
Cardinal Health, carrying a Zacks Rank #2 (Buy) at present, posted a second-quarter fiscal 2026 adjusted EPS of $2.63, exceeding the Zacks Consensus Estimate by 10%. Revenues of $65.6 billion topped the Zacks Consensus Estimate by 0.9%.
CAH has a long-term earnings growth rate of 15% compared with the industry’s 9.6% growth. The company’s earnings outpaced estimates in each of the trailing four quarters, the average surprise being 9.3%.
Align Technology, carrying a Zacks Rank #2 at present, posted a fourth-quarter 2025 adjusted EPS of $3.29, exceeding the Zacks Consensus Estimate by 10.1%. Revenues of $1.05 billion outperformed the Zacks Consensus Estimate by 5.3%.
ALGN has an estimated long-term earnings growth rate of 10.1% compared with the industry’s 9.5% growth. The company’s earnings outpaced estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 6.16%.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
PEN Stock Up Following Q4 Earnings & Revenue Beat, Margins Rise
Key Takeaways
Penumbra, Inc. (PEN - Free Report) reported fourth-quarter 2025 adjusted earnings per share (EPS) of $1.18 compared with 85 cents in the year-ago quarter. The figure surpassed the Zacks Consensus Estimate by 5.36%.
GAAP earnings were $1.20 per share compared with 86 cents in the prior-year period.
For the full year, adjusted EPS came in at $3.84, up 82.9% year over year.
PEN’s Revenues
Penumbra registered revenues of $385.4 million in the reported quarter, up 22.1% year over year on a reported basis and 20.9% at constant exchange rate or CER. The figure topped the Zacks Consensus Estimate by 6.74%.
For the full year, revenues were $1.40 billion, reflecting a 17.5% rise from the year-ago period (16.9% at CER).
Since the Feb. 25 announcement, PEN shares have risen 1.7%, closing at $344.39 on Friday.
Penumbra’s Q4 Results in Detail
The company reports under two geographical segments — the United States and International.
PEN recorded revenues of $299.1 million (77.6% total revenues) in the United States, up 20.6% year over year on a reported basis.
Revenues in the International segment increased 27.7% on a reported basis (up 20.9% in CER) to $86.3 million (22.4% of total revenues).
Penumbra, Inc. Price, Consensus and EPS Surprise
Penumbra, Inc. price-consensus-eps-surprise-chart | Penumbra, Inc. Quote
The company currently reports its product revenues under two categories — Thrombectomy, and Embolization and Access.
The company registered revenues of $254.7 million from sales of Thrombectomy products, up 15.7% on a reported basis and 14.7% at CER.
Sales of Embolization and Access products totaled $130.7 million, up 22.1% on a reported basis and 20.9% at CER.
PEN’s Q4 Margin Performance
In the reported quarter, Penumbra’s gross profit improved 24.4% year over year to $262.1 million. The gross margin expanded 123 basis points (bps) to 68% despite a 17.6% rise in the cost of revenues.
Selling, general and administrative expenses rose 22.4% to $181.1 million. Research and development expenses totaled $21.8 million, up 8.9% year over year. Adjusted operating profit came in at $59.2 million compared with $42.8 million in the comparable 2024 period. The adjusted operating margin expanded 181 bps year over year to 13.4%.
PEN’s Financial Update
Penumbra exited the fourth quarter of 2025 with cash and marketable investments of $544.8 million compared with $340.1 million at the end of 2024.
Penumbra Halts 2026 Guidance
In January 2026, Penumbra announced a definitive agreement to be acquired by Boston Scientific in a cash and stock transaction, valuing the company at $374 per share or approximately $14.5 billion in enterprise value. The transaction is expected to be completed in 2026, subject to PEN stockholders’ approval and the satisfaction of other customary closing conditions. In light of this proposed acquisition, Penumbra stopped providing financial guidance for full-year 2026.
Our Take on PEN Stock
Penumbra exited the fourth quarter of 2025 with better-than-expected earnings and revenues. Sales growth of global thrombectomy products, and global embolization and access products were both driven by the U.S. performance. The expansion of both margins is also highly encouraging.
During the quarter, the company announced results from the landmark STORM-PE randomized controlled trial, which found that the use of mechanical thrombectomy, specifically computer-assisted vacuum thrombectomy, with anticoagulation achieved a superior reduction in right heart strain compared to anticoagulation therapy alone in patients with acute intermediate-high risk pulmonary embolism. Findings also showed significantly greater improvements in thrombus burden reduction, heart rate, oxygen requirement and functional outcomes.
PEN’s Zacks Rank and Key Picks
Currently, Penumbra carries a Zacks Rank #4 (Sell).
Some better-ranked stocks from the broader medical space are Intuitive Surgical (ISRG - Free Report) , Cardinal Health (CAH - Free Report) and Align Technology (ALGN - Free Report) .
Intuitive Surgical, currently sporting a Zacks Rank #1 (Strong Buy), reported a fourth-quarter 2025 adjusted EPS of $2.53, which surpassed the Zacks Consensus Estimate by 12.4%. Revenues of $2.87 billion beat the Zacks Consensus Estimate by 4.7%. You can see the complete list of today’s Zacks #1 Rank stocks here.
ISRG has an estimated long-term earnings growth rate of 15.7% compared with the industry’s 12.7% growth. The company beat earnings estimates in each of the trailing four quarters, the average surprise being 13.24%.
Cardinal Health, carrying a Zacks Rank #2 (Buy) at present, posted a second-quarter fiscal 2026 adjusted EPS of $2.63, exceeding the Zacks Consensus Estimate by 10%. Revenues of $65.6 billion topped the Zacks Consensus Estimate by 0.9%.
CAH has a long-term earnings growth rate of 15% compared with the industry’s 9.6% growth. The company’s earnings outpaced estimates in each of the trailing four quarters, the average surprise being 9.3%.
Align Technology, carrying a Zacks Rank #2 at present, posted a fourth-quarter 2025 adjusted EPS of $3.29, exceeding the Zacks Consensus Estimate by 10.1%. Revenues of $1.05 billion outperformed the Zacks Consensus Estimate by 5.3%.
ALGN has an estimated long-term earnings growth rate of 10.1% compared with the industry’s 9.5% growth. The company’s earnings outpaced estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 6.16%.